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radiation therapy—rhabdomyosarcoma
patient: Case reports and review of literatureKishore Shetty *, Heber TuftLSU Health Sciences Center, Oral and Maxillofacial Surgery, 1100 Florida Avenue,
#127, New Orleans, Louisiana 70119, USAReceived 18 June 2005; accepted 21 June 2005Summary This article describes the dental management in two patients aged 8
and 5 with rhabdomyosarcoma (RMS) post-radiation therapy. The report discusses
some of the common problems faced such as osteoradionecrosis, xerostomia, muco-
sitis, candidiasis, trismus, loss of taste, soft tissue necrosis, and scar tissue forma-
tion and the need for the oral healthcare provider to understand these sequelae in








Rhabdomyosarcoma (RMS) is the most common
soft-tissue sarcoma of childhood and adolescence
involving the head and neck and is the third most
common extracranial solid tumor of childhood
after Wilm’s tumor and neuroblastoma.1–3 A malig-
nant tumor composed of neoplastic mesenchymal
cells, RMS has varying degrees of striated muscle-
cell differentiation.4 Adolescents younger than 20
years of age are mostly diagnosed with this sar-
coma.5 About 65% of these cases are diagnosed in
children under 6 years of age.5 RMS occurs in males741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reser
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E-mail address: kshett@lsuhsc.edu (K. Shetty).more than females. In females RMS has a higher
incidence in the Caucasian race.6,7
Common sites of primary disease include the
head and neck, genitourinary tract, and extremi-
ties.1,2 The head and neck is the most common site
for RMS with about 40% of the cases.5,8,9 This re-
gion can be divided into 3 subsites: the orbit,
non-parameningealnnon-orbitregion, and paramen-
ingeal.5 The most common site of occurrence in the
head and neck is the orbit, followed by the nasal
cavity and the nasopharynx.10 RMS is uncommon
in the oral cavity, and jaw involvement is extre-
mely rare.8,11 The most common site in the oral
cavity is the tongue, followed by the soft palate,
hard palate, and buccal mucosa.8,9 RMS can be de-
scribed by three basic types: embryonal, alveolar,
and pleomorphic.10 Embryonal RMS, occurring inved.
Figure 1 Initial presentation with pain and abscess in
lower left first molar.
Figure 2 Radiolucencies and irregular trabecular pat-
tern with rarefactions on the tip of both roots on lower
left first molar.
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three types and appears within the first 10 years of
life. Alveolar RMS occurs in 20–30% of the cases
and appears between ten to twenty-five years of
age. Pleomorphic RMS is found in less than 5% of
the cases and shows peak prevalence in patients
over forty years of age. Commonly found in the
extremities, pleomorphic RMS cells are loosely ar-
ranged, haphazardly oriented, and exist with vari-
able morphology.10
As the name implies, the cells of embryonal
RMS resemble that of the developing muscle cells
of a six-to-eight-week-old fetus. Common sites for
this cancer are the head and neck, bladder, the
vagina, the prostate, and the testes. Its prognosis
is relatively good to intermediate. Alveolar RMS
receives its name because its cells form hollow
spaces. These cells look like normal muscle cells
of a 10-week-old fetus and are typically found in
the large muscles of the trunk, arms, and legs.
Its prognosis is poor, and it tends to be more
aggressive than the embryonal RMS.12 The alveolar
variant is relatively rare compared to the embryo-
nal form.8,11
Rhabdomyosarcomas are aggressive, frequently
recur, and metastasize via blood and lymph
routes.3,13,14 Lesions involving the posterior mandi-
ble, especially the alveolar variant, have the worst
prognosis.13,14 Combined modality therapy can
cure 60–70% of newly diagnosed patients with
non-metastatic disease. The 5-year survival rate
is 71%. Despite aggressive multimodality treat-
ment, less than 20% of patients with the metastatic
disease are currently cured; the 5-year survival
rate is 27%.4,15
Treatment approaches to RMS incorporate sur-
gery, radiation therapy, and chemotherapy. In sites
such as the head and neck or pelvis, tumors often
cannot be completely removed with surgery; radia-
tion therapy (RT) can eradicate residual tumor
cells in such instances. Early guidelines for RT rec-
ommend doses as high as 5500 to 6000 cGy for con-
trol of the primary tumor site.15
No clear etiologic factors can account for these
malignant neoplastic growths. However, increasing
evidence indicates that gene abnormalities may
play a role in the development of some childhood
malignancies, especially RMS.16 RMS has been asso-
ciated with familial syndromes, such as neurofibro-
matosis, and the Li–Fraumeni syndrome.17
Differential diagnoses of RMS include Ewing sar-
coma, Wilms’ tumor, lymphoma, neuroblastoma,
alveolar soft-part sarcoma, fibrosarcoma, and
leiomyosarcoma.
These case reports demonstrate some effective
post-radiation therapies for RMS patients.Patient #1
An 8-year-old white male patient presented to the
Childrens’ Hospital Dental Clinic with a lower left
facial swelling and pain in lower left first molar
(Fig. 1). The panorex revealed periapical radiolu-
cencies on both root tips and an irregular trabecu-
lar pattern with rarefactions (Fig. 2). The diagnosis
was irreversible pulpitis leading to chronic periapi-
cal abscess and buccal-infected cyst. The patient’s
medical history was significant for embryonal
auricular RMS diagnosed six years ago (Fig. 3).
The surgery took out most of the tumor and the
middle ear. As a result he had limited opening of
his jaw and no hearing in his right ear. Six weeks
of maximum RT of 5900 cGy was followed by
fourteen months of chemotherapy followed the
radiation therapy (RT).
The patient was scheduled to have an extraction
on #19 subsequent to hyperbaric oxygen therapy
using Mark protocol, which entailed 20 dives prior
Figure 5 On the horizontal CT the medial extension of
the lesion can be better appreciated with obvious lateral
expansion and probable violation of the cortical bone as
well.
Figure 3 On the frontal (coronal) CT an expansile
radiolucent lesion is apparent in the ramus area and
appears to extend into the condylar/coronoid regions.
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extraction healing was uneventful with no compli-
cations. Future treatment included frequent re-
calls to watch the progression of his premolars
and second molars.Patient #2
A 5-year-old Caucasian female presented to the
Dental Clinic accompanied by her mother with a
chief complaint of ‘‘jaw is swollen and cannot open
mouth wide enough to clean inside’’ (Fig. 4). Her
medical history was significant for alveolar RMS
stage III, diagnosed 5 years ago and surgicallyFigure 4 Gross facial asymmetry and large swelling of
the right posterior mandible.removed 3 months later (Fig. 5). A coronoidectomy
on the right mandible was performed and metal
plates were placed in the infratemporal fossa and
zygoma regions. Her right mandibular area was
irradiated with 4500 cGy for 6 weeks subsequent
to surgical healing to destroy any remaining parts
of the tumor. She had a history of trismus which
developed after tumor removal, and was presently
practicing postoral muscle stretching. She has no
history of dental restorations or of trauma to the
orofacial region (Fig. 6).
The extraoral exam showed gross facial asym-
metry and a large swelling of the right posterior
mandible. This swelling was firm and tender on pal-
pation. There was a mild lymphadenopathy of the
right submandibular and cervical nodes. Intraoral
exam showed swelling that extended from the right
mandibular canine to right mandibular second pri-
mary molar. Trismus was present with a con-
stricted oral opening of approximately 7 mm
vertically (Fig. 7). She had generalized radiation
caries with an increased occurrence on the side
irradiated, poor oral hygiene, and xerostomia.
Appropriate Medical consults obtained prior to
dental treatment under general anesthesia did
not prescribe any hyperbaric oxygen therapy. The
patient had extensive dental treatment done
involving extractions of unrestorable primary
teeth, multiple stainless steel crowns and resin res-
torations (Fig. 8). All of her teeth were prophy-
laxed with application of topical fluoride varnish.
Figure 6 Initial presentation showing no history of dental restorations or of trauma to the oral facial region.
Figure 7 Constricted oral opening of 7 mm vertically.
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stretching exercises. A follow-up appointment
showed that the extraction sites were healing well
and that the restorations were successful.Figure 8 Panorex post dental treatment involving muDiscussion
Radiation therapy (RT) is a major defense against
RMS and other such diseases. One of the top chal-
lenges in pediatric oncology today is to develop a
cure for the disease and to restrict the develop-
ment of RT late toxicity.17 RT is primarily responsi-
ble for the dental sequelae in patients receiving
treatment for these diseases.19 The special care
dentist needs a strong understanding of these se-
quelae in order to best treat patients.
Radiation reduces or eliminates the reproduc-
tion of neoplastic cells in general and can be used
in conjunction with other therapy, such as surgery
or chemotherapy. It can cure the patient’s disease,
or, as palliative care, it may simply prolong and im-
prove the quality of life. Head and neck radiation is
measured in Megavolts. Generally, the more pene-
tration needed for deeper tissues, the more mega-
voltage radiation is chosen.
Some of the side effects of post-radiation in-
clude delayed eruption of teeth, retarded toothltiple stainless steel crowns and resin restorations.
246 K. Shetty, H. Tuftand bone development, dwarfed teeth, partial ano-
dontia, erosive caries (radiation caries), discolor-
ation of teeth due to dentinal changes, poor
enamel and cervical fracture, osteoradionecrosis,
xerostomia (salivary-gland dysfunction), mucositis
(dose related), candidiasis (moniliasis, thrush),
trismus, loss of taste due to damage to the papillae
of the tongue, soft-tissue necrosis, and scar-tissue
formation.
Osteoradionecrosis (ORN) is one of the most
serious complications of radiation therapy. It oc-
curs in the mandible more frequently than in the
maxilla, probably because of the greater vascular-
ity in the maxilla. ORN is defined as ‘‘a sequence of
radiation, hypovascular–hypocellular–hypoxic tis-
sue formation, and trauma-induced or spontaneous
mucosa breakdown leading to a nonhealing
wound.’’20 In ORN, ionizing radiation leads to oblit-
erative endarteritis with atrophy of skin and sup-
portive tissues that is progressive over time.
Injured tissues become atrophic, often ‘‘dry’’ and
woody, and tolerate wounding very poorly. Ef-
fected tissues lose most or all of their capillary
microcirculation.21 Irradiation affects both bone
matrix and marrow elements. Osteoblast numbers
are decreased, which leads to decreased collagen
production.22 Etiology of ORN depends on the mode
of radiation therapy, daily-dose rate, and radiation
fields. ORN is found in both children and adults.20
Clinical signs and symptoms of ORN are often
associated with the development of cutaneous fis-
tulas, trismus, pain, and masticatory difficulties.
The patient may have a foul odor due to the accu-
mulation of debris in the defect and exposure of
the bone to oral fluids. Exposed bone is usually cov-
ered by grayish-yellow surface coagulum that eas-
ily scrapes off, leaving an avascular bed with a
brownish-yellow color. The mucosa overlying the
bony lesion will frequently have an ulcerated,
rolled border that may bleed when probed. Radio-
graphically, ORN will present as an erosion of the
cortical surface with an underlying, poorly circum-
scribed, radiolucency with nonsclerotic borders.
Interspersed radiopacities, which represent
sequestrum formation, may be seen. Pathological
fractures may also occur in the affected bone.18
Some of the risk factors for the development of
ORN are: the anatomic location of the lesion (the
tongue,floor of the mouth, retromolar region have
a higher incidence of ORN), the dental status prior
to patient pretreatment, dental and gingival trauma
after RT, and the area of bone exposure (attached
gingival mucosa is better than vestibular area).18
To help prevent the occurrence of post-radiation
ORN, the following should be performed prior to
radiation. The non-restorable teeth should beextracted, the salvageable teeth restored, and
periodontal therapy should be completed. The
patient should begin a home-care program, which
would include the use of a topical fluoride, anti-
microbial mouth rinses, and proper brushing and
flossing techniques. Salivary stimulants should be
used to replace and enhance salivary flow. If re-
moval of teeth is indicated before radiation treat-
ment, extractions should be completed with flap
elevation, alveoloplasty, and primary closure of the
flap without tension. Radiation should be delayed
a minimum of 10–14 days after extraction.18
To help prevent the occurrence of postradiation
ORN, after radiation, the patient should begin
treatment for mucositis, oral dryness, and hyposal-
ivation. The patient should learn to use range of
motion exercises to prevent trismus and should
recieve nutritional counseling.18
Hyperbaric oxygen therapy (HBO) in most cases
is needed to help healing.16 HBO is the therapeutic
administration of oxygen at greater than atmo-
spheric pressure for therapeutic purposes. Delivery
of the oxygen must be systemic. It combats osteo-
radionecrosis because it helps revascularize radi-
ated or infected tissue and improves fibroblastic
density. It creates a capillary ingrowth, which
spawns healing of infected tissues.22 The target tis-
sue is not necrotic bone, but the soft tissue and
bone still undamaged and viable. Necrotic bone
must be surgically removed. Therefore, HBO is
used to limit surgical bone removal of nonviable
bone, to enhance healing of the surgical wound,
and to prepare the tissue for reconstruction. Most
pediatric patients adapt to HBO therapy easily once
middle ear pressure is equalized.
Dental caries typically occur during the first year
after RT. To help prevent and treat radiation car-
ies, the patient can floss and brush with 0.4% stan-
nous fluoride toothpaste or use 1.1% sodium
fluoride in a disposable or freshly cleansed flexible
custom fluoride tray over the teeth for 5 min daily.
Extractions should be avoided from portions of the
jaws receiving over 5000 rads; less than 5000 is
acceptable. If extractions are unavoidable for por-
tions receiving over 5000 rads, consider HBO prior
to and after extractions.
The effects of radiation on the salivary glands
can cause xerostomia. Of the serous and mucous
components of saliva, only the mucous components
remain after a second week of radiation treatment,
especially if the major salivary glands are in the
radiation field. Xerostomia treatment may include
frequent sips of water or lemon water, pilocarpine
5–10 mg twice a day, a glycerine swab before
meals, special food preparation, sugarless candy
and gum, and artificial saliva solutions. The patient
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based mouth washes or mouth rinses and alcohol
intake. Also a mouthwash of 1/2 teaspoon of salt
and 1/2 teaspoon of baking soda to a quart of warm
water will remove the viscous component of saliva
from the oral cavity.
Mucositis may start the second week of RT and is
characterized by sloughing of the mucosa and a de-
nuded burning surface which is due to of the rap-
idly dividing epithelial cells. Mucosa may take one
to three months after radiation to return to nor-
mal. Most cases of mucositis are reversed with
the cessation of therapy. Mucositis can usually be
anesthetized with a gentle mixture of benadryl
elixir and kaopectate 1:1 volumetric constituent.
This mixture can be used often to control pain.
Its treatment is palliative and includes mixtures
of maalox, benadryl, and xylocaine formed into a
viscous rinse. Carafate liquid can act as an oral
bandage and can prevent secondary infection of
these lesions.
A good prevention for candidiasis is chlorhexi-
dine 0.12% TID. Treatment of pain associated with
candidiasis includes alkaline mouth rinses
(salt + bicarbonate) and 0.5% povidone–iodine
mouth rinses q2h. Treatments of infection associ-
ated with scandidiasis may include clotrimaxole
troches; fluconazole or nystatin. Loss of taste usu-
ally persists up to 4 months after the end of ther-
apy. Zinc sulfate 220 mg BID can increase taste
perception and may increase salivation.
Active jaw opening exercises can prevent or re-
duce scar-tissue formation and can reduce trismus
during and after radiation therapy. Trismus can
occur progressively after radiation therapy and is
most common when the elevator muscles are in
the field of radiation therapy. A sudden incidence
of trismus may indicate recurrent disease. Tongue
blades inserted between the teeth several times
each day can prevent trismus. This insertion is a
passive stretching exercise to maintain inter-incisal
opening. Moist heat on the muscle experiencing
trismus may make the exercise easier and less
painful.
Chemotherapy, often used with RT to treat RMS,
consists of antineoplastic medications that sup-
press the autoimmune system and/or directly kill
cells. Most antineoplastic agents affect normal
cells, as well as tumor cells.23 Antineoplastic
agents such as vincristine, actinomycin, and cyclo-
phosphamide can interfere with odontogenesis,
causing root shortening, tapering, and blunting,
and can also interfere with amelogenesis, resulting
in hypomineralized enamel defects.8 Chemother-
apy can cause xerostomia, gingival hemorrhage,
oral infections, bacterial overgrowth, herpeticovergrowth, candida overgrowth, mucosal ulcer-
ations, and teeth sensitivity.23
Professional follow-up supervision is a key ele-
ment of successful long-term dental health mainte-
nance after RT.24 An identification of late sequelae
due to RT is vital to afford the long-term survivor
an excellent quality of life.8References
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